TRANSFUSION MEDICINE PROTOCOLS

Normal Immunoglobulin VF

This document should be read in conjunction with the Disclaimer

AIM	To describe the indication, ordering, administration and documentation of Normal Immunoglobulin VF
DESCRIPTION	Normal Immunoglobulin-VF for Intramuscular Use
SPECIFICATIONS	Normal Immunoglobulin-VF is a sterile, preservative-free solution containing 160 mg/mL human plasma proteins and 22.5 mg/mL glycine. The solution has a pH of 6.6. At least 98% of the protein is immunoglobulins (mainly IgG). This product is for intramuscular use. Normal Immunoglobulin-VF Product Information
VIAL SIZE	2 and 5 mL.
INDICATIONS	• Congenital and acquired primary hypogammaglobulinaemia. • Secondary hypogammaglobulinaemia when there is a tendency to recurrent infection such as multiple myeloma, macroglobulinaemia, leukaemia, nephrosis and protein-losing enteropathy. • Susceptible contacts of hepatitis A, measles and poliomyelitis.
CONTRAINDICATIONS AND PRECAUTIONS	Immunoglobulin VF is contraindicated in individuals with • Isolated Immunoglobulin A (IgA) deficiency, unless patient is tested and shown not to have circulating IgA antibodies. • Severe thrombocytopenia or any coagulation disorder that would contraindicate IM injections. Immunoglobulin VF **must not** be administered intravenously because of the potential for anaphylactic reactions. It should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human Immunoglobulin preparations.

CONSUMER INFORMATION	Normal Immunoglobulin-VF Consumer Medicine Information
CONSENT	Written consent is required as Normal Immunoglobulin is manufactured from pooled human plasma. Refer to Transfusion Medicine Protocol WNHS Blood Product Prescription, Informed Consent. And Refusal
DOSE	Dosage varies depending on the clinical indication. Refer to Consultant Haematologist for advice. Refer to the Normal Immunoglobulin-VF Product Information and The Australian Immunisation Handbook for further information on dosing.
ORDERING	Contact Transfusion Medicine Unit (TMU).
ADMINISTRATION	• Two staff to perform checks as per the Clinical Practice Manual, WNHS Pharmacy Medication Checking and Administration processes. • Check Issue label and patient ID. Check right patient, right product, right dose – prescription matches product supplied. If not identical, contact TMU and prescribing doctor. • The product must be used immediately after opening. Any unused solution must be discarded. • Allow product to reach room temperature before administration. • Do not use the product if it appears turbid or contains sediment. • Give slowly by deep inter muscular injection using appropriate sized needle.
OBSERVATIONS	Undertake observations as for all blood products. Vital signs (temperature, pulse, respiration, blood pressure) must be recorded on the observation chart in the medical record. Observe for signs of adverse reactions – Refer to Normal Immunoglobulin-VF Product Information.
ADVERSE REACTIONS	Local tenderness, erythema and stiffness may occur at the injection site and may persist for several hours. For more information refer to Normal Immunoglobulin-VF Product Information. Any adverse reaction should be reported to the Clinical Haematologist and TMU.

	Refer to WNHS Management of Transfusion Reactions and Adverse Events, as a guide to further treatment and management of the patient.
DOCUMENTATION	A record should be kept in the patient's history of the following: • The date and time of infusion • Patients observations and condition during the infusion • Amount given • The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet MR735). This information is important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date.
For further information, refer to product insert Return product to TMU immediately if no longer required. Product should be used for intended patient (issue label) only.	

References

- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals. http://www.transfusion.com.au/blood_products/fractionated_plasma/immunoglobulins
- Australian Government Department of Health, The Australian Immunisation Handbook, 10th Edition, 2013
- CSL Global Normal Immunoglobulin-VF
- CSL Normal Immunoglobulin-VF Product Information.
- Flippin' Blood BloodSafe SA / ARCBS Second Edition June 2012 http://resources.transfusion.com.au/cdm/ref/collection/p16691coll1/id/20

Related policies

- National Safety and Quality Health Service Standards, October 2012. Standard 7: Blood and Blood Products

Related WNHS policies, procedures and guidelines

- WNHS Blood Product Prescription, Consent and Refusal
- WNHS Management of Transfusion Reactions and Adverse Events
- WNHS Pharmacy Medication Checking and Administration
- Neonatology Clinical Care Guidelines
- Obstetrics and Gynaecology Clinical Guidelines
- WNHS Pharmacy Medication Checking and Administration

File path:	WNHS.HAEM.NormalImmunoglobulinVF		
Keywords:	normal immunoglobulin, normal immunoglobulin VF, normal immunoglobulin for intramuscular use, indications for normal immunoglobulin, administration of normal immunoglobulin,, NIG, NIVIg, NIg IM, plasma derived blood products, plasma immunoglobulins, adverse reactions to blood products		
Document owner:	Chair of KEMH Hospital Transfusion Committee		
Author / Reviewer:	Consultant Haematologist, Scientist in Charge Transfusion Medicine, KEMH Transfusion Coordinator		
Date first issued:	01 01 2005		
Last reviewed:	01 12 2015	Next review date:	01 02 2020
Endorsed by:	KEMH Hospital Transfusion Committee	Date:	01 02 2017
Standards Applicable:	NSQHS Standards: 1 Governance, 5 Patient ID/Procedure Matching, 7 Blood Products		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			